Agios Pharma stock price target cut to $32 from $54 at BofA on SCD trial results

RBC Capital has downgraded the stock rating of Agios Pharma following the release of mixed trial data. This decision reflects concerns about the company's performance and future prospects in the market.

Bank of America (BofA) has lowered its stock price target for Progressive to $346, attributing this adjustment to the company's growth in auto policy. This decision reflects BofA's assessment of Progressive's market position and future performance potential.

Bank of America (BofA) has lowered its stock price target for Home Depot to $430, citing softness in the professional backlog. This adjustment reflects ongoing challenges the company faces in a sluggish housing market and rising inflation, which have negatively impacted consumer demand. The sentiment surrounding Home Depot's stock remains negative as it grapples with these economic pressures.

A recent Bank of America survey indicates that investors expect the euro to end 2026 within a range of $1.10 to $1.20, compared to its current value of $1.1587. This sentiment reflects a cautious outlook among investors regarding significant fluctuations in the euro-dollar exchange rate.

BofA has raised its stock price target for Jazz Pharmaceuticals to $247, driven by the company's advancements in cancer drug development. This adjustment reflects positive market sentiment towards Jazz Pharmaceuticals, indicating confidence in its future performance and potential growth in the oncology sector.

A recent Bank of America (BofA) survey indicates that investors are increasing their risk exposure despite signals suggesting a potential market downturn. The survey highlights a growing trend among investors to take on more risk, even as cash positions are flashing a 'sell signal.' This juxtaposition raises concerns about market stability and investor sentiment moving forward.